23andMe Holding Co. has launched a new polygenic risk score (PRS) report for osteoporosis, available to 23andMe+ Premium members. This report assesses an individual's genetic likelihood of developing ...

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker ...

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest ...

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest ...

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (ME), a leading genetic health and biopharmaceutical company, today launched Health Action Plan, a new digital tool ...

On Monday, 23andMe announced its fifth round of layoffs since the beginning of last year. The layoffs impact over 200 people or about 40% of 23andMe’s existing workforce. The genetics health company ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

Regeneron Pharmaceuticals acquiring genetic testing firm 23andMe for $256 million. The deal follows 23andMe’s Chapter 11 bankruptcy protection filing in March. Transaction excludes telehealth provider ...

The new board members are Andre Fernandez, the former chief financial officer of WeWork; Jim Frankola, the former CFO of the enterprise cloud company Cloudera; and Mark Jensen, a tech advisor and ...

It now falls to the company's chief financial and accounting officer, Joe Selsavage, to take on the role of interim CEO. Selsavage joined 23andMe in November 2021 through the acquisition of Lemonaid ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...